Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Montelukast Bluefish

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Montelukast Testmiljö

Montelukast

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246.

  2. Dales RE, Mehdizadeh A, Aaron SD, Vandemheen KL, Clinch J. Sex differences in the clinical presentation and management of airflow obstruction. Eur Respir J. 2006;28:319-22.

  3. Tantisira KG, Colvin R, Tonascia J, Strunk RC, Weiss ST, Fuhlbrigge AL et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med. 2008;178:325-31.

  4. Singulair (montelukast). DailyMed [www]. US National Library of Medicine. [updated 2016-06-30, cited 2017-05-28].

  5. Food and Drug Aministration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SINGULAIR (montelukast sodium). Food and Drug Administration [www]. [updated 2005-07-12, cited 2017-05-28].

  6. Singulair (montelukast). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2023-06-19, cited 2024-03-28]

  7. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996;13:445-8.

  8. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007;120:e702-12.

  9. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.

  10. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma. 2010;47:986-93.

  11. Esposito R, Spaziano G, Giannattasio D, Ferrigno F, Liparulo A, Rossi A et al. Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men. Front Pharmacol. 2019;10:1094.

  12. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol. 2008;121:1365-71.

  13. Singh SB, Weinberger MM, Zimmerman MB, Starner TD. Growth of preschool age children receiving daily inhaled corticosteroids. Allergy Asthma Proc. 2013;34:511-8.

  14. Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012;129:702-707e2.

  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246.
  2. Dales RE, Mehdizadeh A, Aaron SD, Vandemheen KL, Clinch J. Sex differences in the clinical presentation and management of airflow obstruction. Eur Respir J. 2006;28:319-22.
  3. Tantisira KG, Colvin R, Tonascia J, Strunk RC, Weiss ST, Fuhlbrigge AL et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med. 2008;178:325-31.
  4. Singulair (montelukast). DailyMed [www]. US National Library of Medicine. [updated 2016-06-30, cited 2017-05-28].
  5. Food and Drug Aministration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SINGULAIR (montelukast sodium). Food and Drug Administration [www]. [updated 2005-07-12, cited 2017-05-28].
  6. Singulair (montelukast). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2023-06-19, cited 2024-03-28]
  7. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996;13:445-8.
  8. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007;120:e702-12.
  9. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
  10. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma. 2010;47:986-93.
  11. Esposito R, Spaziano G, Giannattasio D, Ferrigno F, Liparulo A, Rossi A et al. Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men. Front Pharmacol. 2019;10:1094.
  12. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol. 2008;121:1365-71.
  13. Singh SB, Weinberger MM, Zimmerman MB, Starner TD. Growth of preschool age children receiving daily inhaled corticosteroids. Allergy Asthma Proc. 2013;34:511-8.
  14. Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012;129:702-707e2.
  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]